A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Exclusion Criteria

• •NSCLC with histology of large cell neuroendocrine carcinoma, sarcomatoid carcinoma, or NSCLC not otherwise specified
• •Small cell lung cancer (SCLC) histology or NSCLC with any component of SCLC
• •Any prior therapy for lung cancer
• •Active or history of autoimmune disease or immune deficiency
• •History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
• •Active tuberculosis
• •Significant cardiovascular disease
• •NSCLC with an activating EGFR mutation or ALK fusion oncogene
• •Known c-ros oncogene 1 (ROS1) rearrangement
• •History of malignancy other than NSCLC within 5 years prior to screening, with the exception of malignancies with negligible risk of metastasis or death
• •Severe infection within 4 weeks prior to initiation of study treatment or any active infection that, in the opinion of the investigator, could impact patient safety
• •Prior treatment with CD127 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, anti-TIGIT, and anti-PD-L1 therapeutic antibodies
• •Treatment with systemic immunostimulatory agents
• •Treatment with systemic immunosuppressive medication
• •Pregnancy or breastfeeding